<clinical_study>
<study_id>
<org_name>
  Amylin
</org_name>
<org_full_name>
Amylin   Pharmaceuticals, Inc. 
</org_full_name>
<org_study_id>
  2993-114
</org_study_id>
<secondary_id>
</secondary_id>
<nct_id>
  NCT00097500
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase 3, Randomized, Open Label, Comparator Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
Amylin   Pharmaceuticals, Inc. 
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Eli Lilly and Company
</agency>
</sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Lisa Porter, MD, Study Director
</name_title>
<organization>
  Amylin Pharmaceuticals
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<regulatory_authority>
  Finland: National Agency for Medicines
</regulatory_authority>
<regulatory_authority>
  Netherlands: Medicines Evaluation Board (MEB)
</regulatory_authority>
<regulatory_authority>
  Sweden: Medical Products Agency
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus&#174; injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Active, not recruiting
</status>
<date>
2008-09 
</date>
</status_block>
<start_date>
<date>
  2004-09
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date
 type="Anticipated"
>
<date>
  2009-12
</date>
</last_follow_up_date>
<primary_compl_date
 type="Anticipated"
>
<date>
  2009-12
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  To compare beta-cell function after intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin.
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  To compare postprandial beta-cell function after long-term therapy with exenatide or insulin glargine in subjects with type 2 diabetes mellitus.
</measure>
<time_frame>
  122 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  To compare the effects of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin with respect to various pharmacodynamic measurements as well as safety and tolerability.
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  To compare the effects following cessation of intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin on various pharmacodynamic measurements.
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  To compare the effects following cessation of long-term intensified therapy with exenatide or insulin glargine in subjects with type 2 diabetes treated with metformin on various pharmacodynamic measurements.
</measure>
<time_frame>
  122 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Anticipated"
>
  75
</enrollment>
<condition>
  Type 2 Diabetes Mellitus
</condition>
<arm_group>
<arm_group_label>
  1
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  2
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  exenatide
</primary_name>
<description>
<textblock>
  subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<other_name>
  Byetta
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin glargine
</primary_name>
<description>
<textblock>
  subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
</textblock>
</description>
<arm_group_label>
  2
</arm_group_label>
<other_name>
  Lantus
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - HbA1c between 6.6% and 9.5%, inclusive.
    - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.
    - Treated with a stable dose of metformin for at least 3 months prior to screening.  
 
  Exclusion Criteria:
    - Patients previously in a study using exenatide.
    - Treated with oral anti-diabetic medications other than metformin within 3 months of screening.
    - Treated with insulin within 3 months of screening.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
  75 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Lisa Porter, MD
</name>
<affiliation>
<agency>
  Amylin Pharmaceuticals
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Helsinki
</city>
<state>
</state>
<zip>
</zip>
<country>
  Finland
</country>
</address>
</facility>
<status>
 Active, not recruiting 
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Amsterdam
</city>
<state>
</state>
<zip>
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
 Active, not recruiting 
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Goteborg
</city>
<state>
</state>
<zip>
</zip>
<country>
  Sweden
</country>
</address>
</facility>
<status>
 Active, not recruiting 
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  diabetes
</keyword>
<keyword>
  exenatide
</keyword>
<keyword>
  exendin-4
</keyword>
<keyword>
  Amylin
</keyword>
<keyword>
  Lilly
</keyword>
<initial_release_date>
  2004-11-24
</initial_release_date>
<last_release_date>
2008-09-30 
</last_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
